臨床微生物學市場－全球產業規模、佔有率、趨勢、機會及預測（依產品、疾病、地區及競爭格局分類，2021-2031年）

全球臨床微生物學市場預計將從 2025 年的 54.7 億美元成長到 2031 年的 73.8 億美元，複合年成長率為 5.12%。

該領域的核心重點是針對病原微生物（包括細菌、病毒、真菌和寄生蟲）進行專業檢測，以確保感染疾病的準確診斷和治療。推動此領域發展的主要因素是感染疾病的上升趨勢，以及快速診斷結果對於改善急診護理中患者照護的重要性日益凸顯。此外，自動化設備和分子診斷技術的應用提高了檢查室效率，實現了現代醫療系統所需的高通量處理，為先進試劑和設備的應用創造了有利條件。

然而，市場面臨著一個重大障礙，即合格的實驗室專業嚴重短缺，而這些專業人員對於監督複雜的診斷工作流程至關重要。人才短缺造成了檢測瓶頸，並限制了醫療機構採用新技術的能力。美國臨床病理學會2024年的職缺調查顯示，17個實驗室專業中有10個專業的員工流動率正在上升，凸顯了問題的嚴重性。這進一步加劇了支持市場持續擴張所需的技能人才短缺問題。

市場促進因素

全球感染疾病和流行病的日益普及是臨床微生物市場的主要驅動力，也迫切需要擴大診斷能力。隨著病原體在各地傳播的加劇，醫療衛生系統被要求升級其檢查室基礎設施，以應對不斷成長的患者數量並確保嚴格的感染控制措施。日益加重的疾病負擔意味著診斷耗材和設備的使用量增加，因為準確識別對於有效治療至關重要。例如，根據世界衛生組織（世衛組織）發布的《2024年全球結核病報告》，預計2023年全球新增結核病病例將達到約820萬例，這將是自1995年開始全球監測以來的最高數字，凸顯了對強大的微生物學服務的迫切需求。

同時，分子診斷技術的進步正在改變市場模式，它能夠快速、高通量地鑑定病原體，避免了傳統培養方法帶來的延誤。檢查室擴大使用自動化症候群檢測平台，這些平台可在數小時內提供可操作的結果，這對複雜的感染疾病管理和藥物管理專案至關重要。這一趨勢反映在該行業的強勁表現中，生物梅里埃公司發布的《2024年第三季業務回顧》顯示，非呼吸系統專科分子檢測組合的銷售額成長了18%。此外，應對抗菌素抗藥性的迫切性也推動了這一趨勢，健康指標與評估研究所（IHME）2024年的預測也證實了這一點。如果不採取行動，抗菌素抗藥性可能導致2025年至2050年間全球超過3,900萬人死亡。

市場挑戰

全球臨床微生物學市場面臨的一大障礙是合格實驗室專業（包括熟練的微生物學家和臨床實驗室技術人員）的嚴重短缺。這種人才短缺嚴重限制了診斷機構的運作能力，並在檢測流程中造成了顯著的瓶頸。隨著醫療系統努力應對日益成長的檢體量，人才不足導致檢體處理和診斷結果發布延遲。因此，檢查室往往被迫限制檢測項目或延後採用需要專業監管的先進分子和自動化技術，減緩了這些重要創新技術的普及應用。

這種限制的嚴重性在招聘困難中顯而易見；美國臨床病理學會2025年報告稱，實驗室技術人員的招聘流程顯著延長。該學會指出，許多科室需要三到十二個月的時間才能填補空缺，這種延誤擾亂了實驗室運作的連續性，並阻礙了服務根據需求進行擴展。最終，勞動力短缺限制了臨床微生物產品的潛在市場，因為人手不足的檢查室很難證明購買新設備或擴充試劑庫存的資本支出是合理的，畢竟沒有足夠的人員來操作這些設備。

市場趨勢

透過先進的就地檢驗設備實現診斷服務的去中心化，正在改變臨床微生物學，將複雜的分子檢測從中心檢查室轉移到更靠近患者的場所。這項轉變的驅動力在於縮短嚴重感染疾病檢測結果的等待時間，並使臨床醫生能夠立即做出基於循證醫學的治療選擇，而無需等待批量檢測結果。製造商正在透過緊湊型、全自動平台來滿足這一需求，這些平台可在幾分鐘內提供檢查室層級的分子檢測結果。生物梅里埃公司於2025年3月發布的「2024年財務業績」印證了這一快速普及的趨勢，該業績顯示，其SPOTFIRE照護現場解決方案的銷售額達到約9500萬歐元，超過了年度目標，並且全球安裝量達到3000台。

同時，利用次世代定序（NGS）技術的基因組監測和總體基因體學正從小眾研究領域走向常規臨床實踐。與針對特定病原體的傳統方法不同，NGS可在單次運行中提供對新型菌株的無偏鑑定和全面的抗菌藥物抗藥性譜分析，這對於追蹤醫院感染爆發和管理複雜感染疾病至關重要。對這項技術的日益依賴也體現在財務業績：2025年9月，牛津奈米孔技術公司公佈其臨床市場部門上半年收入按外匯匯率計算成長了52.9%，這表明奈米孔定序正迅速融入診斷工作流程。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球臨床微生物學市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品（測試設備、自動化培養系統、試劑等）
  • 依疾病分類（呼吸系統疾病、血液感染疾病、消化系統疾病、性行為感染、尿道感染、牙周病、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美臨床微生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲臨床微生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區臨床微生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲臨床微生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

10. 南美洲臨床微生物學市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球臨床微生物市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories Inc.
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• Bruker Corporation
• Bio-Rad Laboratories, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Clinical Microbiology Market is projected to expand from USD 5.47 Billion in 2025 to USD 7.38 Billion by 2031, reflecting a compound annual growth rate of 5.12%. This sector centers on the specialized laboratory analysis of pathogenic microorganisms-including bacteria, viruses, fungi, and parasites-to ensure accurate diagnosis and treatment of infectious diseases. Growth is largely driven by the rising burden of infectious conditions and the critical need for rapid diagnostic outcomes to improve patient care in acute settings. Additionally, the adoption of automated instrumentation and molecular diagnostic technologies enhances laboratory efficiency, enabling the high-throughput processing required by modern healthcare systems and fostering a favorable environment for advanced reagents and instruments.

However, the market encounters a substantial obstacle in the form of a severe shortage of qualified laboratory professionals needed to oversee complex diagnostic workflows. This gap in the workforce generates testing bottlenecks and restricts the ability of healthcare facilities to implement new technologies. Highlighting the severity of this issue, the American Society for Clinical Pathology's 2024 vacancy survey revealed that retirement rates had risen in ten out of seventeen laboratory departments, further exacerbating the scarcity of skilled personnel required to support sustained market expansion.

Market Driver

The escalating global prevalence of infectious diseases and epidemics acts as a major driver for the clinical microbiology market, necessitating an urgent expansion of diagnostic capabilities. As pathogen transmission increases across various regions, healthcare systems must upgrade their laboratory infrastructure to handle growing patient volumes and enforce strict infection control measures. This rise in disease burden leads to higher usage of diagnostic consumables and instruments, as accurate identification is essential for effective treatment. For instance, the World Health Organization's "Global Tuberculosis Report 2024" noted that approximately 8.2 million people were newly diagnosed with tuberculosis in 2023, the highest number since global monitoring began in 1995, underscoring the critical need for robust microbiology services.

Concurrently, technological strides in molecular diagnostics are transforming the market by facilitating rapid, high-throughput pathogen identification that avoids the delays of traditional culture methods. Laboratories are increasingly utilizing automated syndromic testing platforms to provide actionable results in hours, a shift that is vital for managing complex infections and stewardship programs. This trend is reflected in strong industry performance; bioMerieux's "Third-Quarter 2024 Business Review" reported an 18% sales increase for specialized non-respiratory molecular panels. Furthermore, the urgency to combat antimicrobial resistance drives this adoption, as evidenced by Institute for Health Metrics and Evaluation forecasts in 2024, which predicted that without intervention, antimicrobial resistance could cause over 39 million deaths globally between 2025 and 2050.

Market Challenge

A primary hurdle impeding the Global Clinical Microbiology Market is the acute shortage of qualified laboratory professionals, including skilled microbiologists and medical laboratory scientists. This workforce scarcity severely constrains the operational capabilities of diagnostic facilities, causing substantial bottlenecks in testing workflows. As healthcare systems attempt to manage rising specimen volumes, the insufficient workforce delays sample processing and the release of diagnostic results. Consequently, laboratories often have to limit their test menus or postpone the adoption of advanced molecular and automated technologies that demand specialized supervision, thereby slowing the uptake of these critical innovations.

The severity of this constraint is evident in recruitment difficulties; in 2025, the American Society for Clinical Pathology reported that hiring processes for laboratory staff have become significantly prolonged. The association noted that many departments now take between three months and a year to fill open positions, a delay that disrupts laboratory continuity and hinders the ability to scale services to meet demand. Ultimately, this labor deficit limits the addressable market for clinical microbiology products, as understaffed laboratories find it difficult to justify capital expenditures on new instrumentation or expanded reagent inventories without the personnel to operate them.

Market Trends

The decentralization of diagnostic services through advanced point-of-care testing devices is reshaping clinical microbiology by relocating complex molecular testing from central labs to near-patient environments. This transition is motivated by the need to shorten turnaround times for critical infections, allowing clinicians to make immediate, evidence-based treatment choices instead of waiting for batch-processed results. Manufacturers are meeting this demand with compact, fully automated platforms that provide laboratory-quality molecular results in minutes. This rapid adoption is illustrated by bioMerieux's "2024 Financial Results" from March 2025, which reported that sales for their SPOTFIRE point-of-care solution reached nearly €95 million, exceeding annual targets with a global installed base of 3,000 units.

In parallel, the application of Next-Generation Sequencing (NGS) for genomic surveillance and metagenomics is moving from niche research into routine clinical practice. Unlike traditional methods targeting specific pathogens, NGS provides an unbiased mechanism to identify novel strains and comprehensive antimicrobial resistance profiles in a single run, which is essential for tracking hospital-acquired outbreaks and managing complex infections. The increasing reliance on this technology is reflected in financial results; Oxford Nanopore Technologies reported in September 2025 that revenue in their clinical market segment rose by 52.9% on a constant currency basis for the first half of the year, highlighting the swift integration of nanopore sequencing into diagnostic workflows.

Key Market Players

• bioMerieux SA
• Becton, Dickinson and Company
• Danaher Corporation
• Abbott Laboratories Inc.
• Hologic, Inc.
• F. Hoffmann-La Roche Ltd
• Bruker Corporation
• Bio-Rad Laboratories, Inc.

Report Scope

In this report, the Global Clinical Microbiology Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Clinical Microbiology Market, By Product

• Laboratory Instruments
• Automated Culture System
• Reagents
• Others

Clinical Microbiology Market, By Disease

• Respiratory Diseases
• Bloodstream Infection
• Gastrointestinal Diseases
• Sexually Transmitted Diseases (STDs)
• Urinary Tract Infections
• Periodontal Diseases
• Others

Clinical Microbiology Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Clinical Microbiology Market.

Available Customizations:

Global Clinical Microbiology Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Clinical Microbiology Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Laboratory Instruments, Automated Culture System, Reagents, Others)
  • 5.2.2. By Disease (Respiratory Diseases, Bloodstream Infection, Gastrointestinal Diseases, Sexually Transmitted Diseases (STDs), Urinary Tract Infections, Periodontal Diseases, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Clinical Microbiology Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Disease
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Clinical Microbiology Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Disease
  • 6.3.2. Canada Clinical Microbiology Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Disease
  • 6.3.3. Mexico Clinical Microbiology Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Disease

7. Europe Clinical Microbiology Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Disease
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Clinical Microbiology Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Disease
  • 7.3.2. France Clinical Microbiology Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Disease
  • 7.3.3. United Kingdom Clinical Microbiology Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Disease
  • 7.3.4. Italy Clinical Microbiology Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Disease
  • 7.3.5. Spain Clinical Microbiology Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Disease

8. Asia Pacific Clinical Microbiology Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Disease
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Clinical Microbiology Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Disease
  • 8.3.2. India Clinical Microbiology Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Disease
  • 8.3.3. Japan Clinical Microbiology Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Disease
  • 8.3.4. South Korea Clinical Microbiology Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Disease
  • 8.3.5. Australia Clinical Microbiology Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Disease

9. Middle East & Africa Clinical Microbiology Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Disease
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Clinical Microbiology Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Disease
  • 9.3.2. UAE Clinical Microbiology Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Disease
  • 9.3.3. South Africa Clinical Microbiology Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Disease

10. South America Clinical Microbiology Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Disease
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Clinical Microbiology Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Disease
  • 10.3.2. Colombia Clinical Microbiology Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Disease
  • 10.3.3. Argentina Clinical Microbiology Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Disease

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Clinical Microbiology Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. bioMerieux SA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Becton, Dickinson and Company
• 15.3. Danaher Corporation
• 15.4. Abbott Laboratories Inc.
• 15.5. Hologic, Inc.
• 15.6. F. Hoffmann-La Roche Ltd
• 15.7. Bruker Corporation
• 15.8. Bio-Rad Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer